|1.||Dhalla, Naranjan S: 9 articles (07/2005 - 07/2002)|
|2.||Takeda, Nobuakira: 7 articles (06/2005 - 07/2002)|
|3.||Shao, Qiming: 5 articles (06/2005 - 08/2004)|
|4.||Ren, Bin: 5 articles (06/2005 - 07/2002)|
|5.||Matsuoka, Hiroaki: 4 articles (09/2010 - 12/2002)|
|6.||Saini, Harjot K: 4 articles (07/2005 - 08/2004)|
|7.||Tappia, Paramjit S: 4 articles (06/2005 - 09/2002)|
|8.||Nagai, Ryozo: 3 articles (04/2012 - 01/2008)|
|9.||Ishimitsu, Toshihiko: 3 articles (09/2010 - 01/2002)|
|10.||Narita, H: 3 articles (05/2001 - 06/2000)|
07/01/1994 - "Furthermore, none of the rats treated with imidapril showed recurrence of stroke, and their survival rate was improved. "
05/01/2000 - "Ogiku et al. reported that one such inhibitor, imidapril, significantly prolonged survival in stroke-prone spontaneously hypertensive rats (SHRSP). "
01/01/1999 - "Imidapril-induced reduction of cerebrovascular damage, which presumably occurs in the brain after stroke, may account for the inhibitory effects of imidapril on lesion formation and learning impairment."
01/01/1999 - "Imidapril thus suppressed progression of neurological deficits with loss of learning ability following onset of stroke, and also suppressed formation of oedema in the brain and decreased the number of lesions in other organs. "
01/01/1999 - "In three-panel runway testing, learning deficits did not develop significantly in the imidapril-treated group, and was comparable to that in the non-salt-loaded/non-stroke group. "
|2.||Hypertension (High Blood Pressure)
04/01/2007 - "In this study, we investigated the effects of a non-depressor dose of imidapril on organ damage induced by diabetes and hypertension. "
01/01/2007 - "In clinical trials, oral imidapril was an effective antihypertensive agent in the treatment of mild to moderate essential hypertension. "
12/01/2006 - "The trial was conducted at 8 centers across Portugal and Spain (the Iberian Multicenter Imidapril Study on Hypertension [IMISH] Study Group). "
04/01/2008 - "One daily dose of imidapril taken either in the morning or at bedtime lowered morning HBP, indicating that imidapril is useful for controlling morning hypertension."
04/01/2008 - "We investigated the effect of the timing of imidapril administration in patients with morning hypertension (home blood pressure [HBP] in the morning [morning HBP] > or =135/85 mmHg). "
05/01/2007 - "Clinical evaluation of imidapril in congestive heart failure in dogs: results of the EFFIC study."
12/01/1998 - "High- versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril."
01/01/1996 - "To study the haemodynamic profile and tolerability of imidapril, a new long-acting ACE inhibitor, and to investigate the effect of inhibition of circulating ACE on blood pressure in patients with stable chronic heart failure. "
05/01/2007 - "The clinical efficacy and safety of imidapril were evaluated in dogs that presented with mild to severe congestive heart failure (New York Heart Association stage II to IV) by comparing the success rate of imidapril with a positive control by a non-inferiority approach. "
09/01/2006 - "Imidapril in heart failure."
06/01/1996 - "Macroscopic and microscopic pathology in imidapril-treated groups was milder than that in control animals in general, but differences were not statistically significant when animals were divided into survivors and fatalities except for the presence of mural thrombus in the heart. "
08/01/1999 - "Oral treatment with 5 mg/kg imidapril 1 h before induction of thrombosis resulted in a significant reduction in thrombus weight, whereas candesartan did not affect thrombus weight under the same treatment conditions. "
05/01/2000 - "Protective effects of imidapril on He-Ne laser-induced thrombosis in cerebral blood vessels of stroke-prone spontaneously hypertensive rats."
08/01/1999 - "These results suggest that imidapril, but not the AT1 receptor antagonist, candesartan, enhances fibrinolysis via a reduction of aortic PAI-1 levels by inhibiting ACE and prevents thrombus formation in SHRs."
08/01/1999 - "Imidapril, an angiotensin-converting enzyme inhibitor, inhibits thrombosis via reduction in aortic plasminogen activator inhibitor type-1 levels in spontaneously hypertensive rats."
|5.||Renal Insufficiency (Renal Failure)
03/01/1998 - "The smallest imidapril dose which is clinically effective should be used in patients with severe renal insufficiency."
04/01/2006 - "Background characteristics such as age, gender ratio, causes of renal failure, duration of hemodialysis, body mass index and pre-dialysis blood pressure were comparable between the placebo and the imidapril groups. "
02/01/2007 - "Clearance of imidapril, an Angiotensin-converting enzyme inhibitor, during hemodialysis in hypertensive renal failure patients: comparison with quinapril and enalapril."
|1.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|2.||Messenger RNA (mRNA)
|3.||Proteins (Proteins, Gene)
|10.||Acetylcholine (Acetylcholine Chloride)
|1.||Renal Dialysis (Hemodialysis)